3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
61
Phase 1/2
22
Phase 1
18
Phase EARLY_PHASE1
4
Phase 3
3
Phase 4
1
Phase 2/3
1
Status
Recruiting
91
Completed
81
Active not recruiting
70
Terminated
17
Not yet recruiting
15
Unknown
6
Withdrawn
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Conditions
Stomach Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
22
Carboplatin
15
Radiotherapy
13
Paclitaxel
11
Gemcitabine
10
Rituximab
9
Fluorouracil
9
Drug Therapy
6
Dexamethasone
5
Cyclophosphamide
5
Capecitabine
5
Bevacizumab
5
Vinorelbine
4
Pemetrexed
4
Nivolumab
4
Methotrexate
4
Etoposide
4
Docetaxel
4
Bendamustine Hydrochloride
4
spartalizumab
3
pertuzumab
3
pembrolizumab
3
fludarabine
3
Vincristine
3
Trastuzumab
3
Surgical Procedures, Operative
3
Standard of Care
3
Prednisone
3
Oxaliplatin
3
Lenalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Withdrawn
×
pembrolizumab
×
Clear all
NCT05791097
2023-07-24
AdvanTIG-306
Novartis
Phase 3
Withdrawn
NCT04859582
2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3
Withdrawn
NCT03881111
2020-02-11
KEYNOTE-590
Merck Sharp & Dohme LLC
Phase 3
Withdrawn